←
Vibe Bio2,955 posts
Vibe Bio avatar

Vibe Bio

@VibeBio

Every cure for every community. Join us.

◷ Joined November 2021▧ 332 Photos and videos
Vibe Bio avatar
Vibe Bio@VibeBio·6 Nov 2025

When time is short, you need clarity. Vibe Bio’s AI, @incitedotorg was able to build & pursue a defensible shortlist in weeks — not months — balancing IP, manufacturability, safety, and route. Dive deeper: hubs.ly/Q03N-7FJ0 #DrugDev #AI #RareDisease #Biotech #casestudy

Vibe Bio avatar
Vibe Bio@VibeBio·3 Nov 2025

Knowledge silos, churned teams, conflicting decks — these are the killers of good BD decisions. AI can stitch together memory and context to help your team move fast and smart. More here: bit.ly/493I2qr #Biotech #AI #BusinessDevelopment

Vibe Bio avatar
Vibe Bio@VibeBio·28 Oct 2025

“Humans might take six months … and still miss opportunities.” AI helped @incitedotorg re-rank assets quickly, eliminating poor fits and adding new ones, and avoid bias in rare disease diligence. Story here ➝ hubs.ly/Q03N-gkc0 #RareDisease #AI #Biotech #casestudy

Vibe Bio avatar
Vibe Bio@VibeBio·23 Oct 2025

BD teams in biopharma can’t afford to forget their past. AI lets you build a memory layer so you don’t re-evaluate the same assets, duplicate outreach, or miss red flags. Read why: 🔗 bit.ly/4n7HyTK #Biotech #AI #BusinessDevelopment

Vibe Bio avatar
Vibe Bio@VibeBio·17 Oct 2025

.@incitedotorg needed prioritized compounds in liposarcoma fast. With Vibe Bio’s AI, they built a defensible shortlist in weeks — not months — balancing IP, manufacturability, safety, and route. Learn more now: hubs.ly/Q03N-kJC0 #RareDisease #AI #Biotech #casestudy

PRV Watch avatar
⟳ Vibe Bio retweeted
PRV Watch@PRVWatch·19 Sep 2025

Stealth receives accelerated approval for elamipretide in Barth Syndrome and with it a priority review voucher. Third attempt at approval and the priority review voucher likely saves the company.

PRV Watch@PRVWatch22 Aug 2025

The FDA has accepted the now third NDA submission from Stealth BioTherapeutics, for elamipretide in Barth Syndrome (rare, genetic disorder). I have put together a timeline below of the very tortuous history between Stealth and the FDA. • Dec ’16 - Stealth submits a protocol to the FDA to evaluate elamipretide in patients with Barth syndrome. • Nov ’17 - FDA grants Fast Track designation. • Mar ’18 - FDA grants Orphan Drug designation. • Jan ’19 - Stealth meets with the FDA, indicating its intent to submit an NDA. • Mar ’20 - FDA grants Rare Pediatric Disease designation. • Jan ’19 to May ’21 - Several meetings with the FDA. FDA states existing data is unlikely to support filing and recommends a new phase 3 trial. • Aug ’21 - Stealth submits an NDA for Barth syndrome despite prior FDA feedback. • Oct ’21 - FDA issues refuse-to-file letter • Nov ’21 - Stealth and the FDA discuss the refuse-to-file letter. FDA continue to recommend a new phase 3 trial. Stealth informs the FDA of their intent to resubmit the NDA without conducting a new trial. • Aug ’22 - Stealth takes company private. • Dec ’23 - The Barth Syndrome Foundation submits a petition to the FDA advocating for a fair, equitable and appropriate review. • Jan ’24 - Stealth resubmits the NDA. • Mar ’24 - FDA accepts the NDA (Standard Review) to conduct a more detailed review of the data and plans to convene an advisory committee for external input. • Apr ’24 - FDA upgrades the review to Priority Review. • Oct ’24 - The Cardiovascular and Renal Drugs Advisory Committee votes 10–6 that elamipretide is effective for treating patients with Barth syndrome. • Jan ’25 - Following the AdCom, the FDA requests additional data constituting a major amendment. The PDUFA date is extended by three months. • Apr ’25 - FDA misses the PDUFA date. • May ’25 - FDA issues a Complete Response Letter. Stealth cuts its workforce by ~30%. • May ’25 - FDA responds to Dec ’23 petition. • 18 Aug ’25 - Stealth resubmits the NDA following feedback from the FDA, seeking accelerated approval based on an intermediate clinical endpoint, using data already included in prior submissions. • 21 Aug ’25 - FDA accepts the resubmission with goal date of 26 September 2025.

Post attachment
Daphne Zohar avatar
⟳ Vibe Bio retweeted
Daphne Zohar@daphnezohar·15 Oct 2025

At the #StatusList dinner last night I was asked what I would change about our industry. My response: the likelihood of making it from discovery to FDA approval is ~1% & takes 10-15 yrs yet the incentives focus only on rewarding the successes w/ so much waste & lost knowledge. We need to find mechanisms to better share & recognize the learnings from the failures, whether they relate to clinical design/execution errors or learnings for a class of targets. What is one thing you would change about our industry?

Post attachmentPost attachment
Vibe Bio avatar
Vibe Bio@VibeBio·2 Oct 2025

CEO & Co-Founder, @aloktayi, PhD, will be part of a panel on about AI in healthcare and how it can drive a healthier, more resilient future. Join him and other world leaders at the STS Forum 2025 in Kyoto on October 6, 2025 10:40-12:40 (120 min). 👉 bit.ly/48R1vKO

Merck avatar
⟳ Vibe Bio retweeted
Merck@Merck·21 May 2025

We are shaping the future of oncology with one of the largest clinical development programs in the industry. We’re focused on expanding into new tumor types and extending into earlier lines of disease. Learn more about where we’re focusing our oncology research efforts.

0:27